scholarly journals Comparison of Treatment Goals between Users of Biological and Non-Biological Therapies for Treatment of Psoriasis in Japan

2021 ◽  
Vol 10 (24) ◽  
pp. 5732
Author(s):  
Yukari Okubo ◽  
Ann Chuo Tang ◽  
Sachie Inoue ◽  
Hitoe Torisu-Itakura ◽  
Mamitaro Ohtsuki
Keyword(s):  
Disease Severity ◽  
Treatment Satisfaction ◽  
Secondary Analysis ◽  
Severity Index ◽  
Treatment Goals ◽  
Cross Sectional ◽  
Logistic Regression Models ◽  
Patient Reported ◽  
Related Quality ◽  
Health Related

Background: Previously, our cross-sectional observational study in Japan revealed high (68%) discordance within treatment goals between psoriasis patients and their physicians. Objective: This secondary analysis aimed to determine whether patient and physician users of biologics have higher treatment goals than users of non-biologics. Methods: A survey for both patients and physicians on background characteristics, disease severity, treatment goals, treatment satisfaction, and health-related quality of life was conducted at 54 sites. Association between treatment goals and biologic/non-biologic users was assessed using ordinal logistic regression models. Results: In total, 449 patient-physician pairs agreed to participate; 425 completed the survey and were analyzed. More biologic users than non-biologic users reported complete clearance (Psoriasis Area and Severity Index 100) as a treatment goal (patient-reported: 23.6% vs. 16.1%; physician-reported: 26.9% vs. 2.2%). Biologic users were significantly associated with higher treatment goals than non-biologic users (patient-reported: 1.8 (1.15–2.87) (odds ratio (9 5% CI)), p = 0.01; physician-reported: 11.0 (5.72–21.01), p < 0.01). Among biologic users, higher treatment goals were associated with higher treatment satisfaction (patient- and physician-rated); lower treatment goals were associated with back lesions and increasing patient age (patient-rated) and higher disease severity (physician-rated). Conclusion: Use of biologics among patients with psoriasis was associated with higher treatment goals. Further use of biologics contributed to treatment satisfaction. Appropriate treatment goals that are shared among patients and their physicians may improve treatment outcomes.

scholarly journals Health-related quality of life in porphyria cutanea tarda: a cross-sectional registry based study

2020 ◽  
Vol 18 (1) ◽  
Author(s):  
Janice Andersen ◽  
Janne Thomsen ◽  
Åshild Rostad Enes ◽  
Sverre Sandberg ◽  
Aasne K. Aarsand
Keyword(s):  
Quality Of Life ◽  
Disease Activity ◽  
Porphyria Cutanea Tarda ◽  
Bodily Pain ◽  
Health Related Quality ◽  
Cross Sectional ◽  
Patient Reported ◽  
Related Quality ◽  
Health Related

Abstract Background Porphyria cutanea tarda (PCT) is a rare, photosensitive disease characterized by skin fragility and blistering on sun-exposed areas. There is little previous research on how this condition affects health-related quality of life (HRQoL) and to the best of our knowledge this is the largest sample of PCT patients surveyed about their HRQoL. The aims of this study were to describe HRQoL, symptoms, susceptibility factors, disease activity and treatment in patients with PCT, and investigate the associations between these factors. Methods This is a cross-sectional, retrospective study based on patient-reported outcome and laboratory data. The Norwegian Porphyria Centre diagnoses all patients with PCT in Norway, all of whom are invited to participate in the Norwegian Porphyria Registry. Between December 2013–2015, 111 patients received a postal questionnaire and invitation to participate. Results Sixty-eight persons responded, with seven being excluded due to prolonged response time or missing information, resulting in 61 participants in the final analyses (55%). Median age was 60 years and 33 were female. We found a moderate negative relationship between the type and localisation of PCT symptoms and both mental (r = −.354 p < 0.01) and physical (r = −.441, p < 0.01) aspects of HRQoL. Participants who had started treatment when answering the questionnaire reported significantly better physical functioning and less bodily pain than those who had not started treatment. We did not observe an association between biochemical markers of disease activity and symptoms or HRQoL. Itching, a symptom that has received little attention in PCT was reported by 59% of the participants. Conclusions Our results show that reduced HRQoL is associated with more symptoms and not having started treatment. PCT is a rare disease, and there is a need for the development of best-practice guidelines to facilitate good patient care.

scholarly journals Treatment Satisfaction and Quality of Life among Type 2 Diabetes Patients: A Cross-Sectional Study in West Bank, Palestine

2020 ◽  
Vol 2020 ◽  
pp. 1-8 ◽  
Author(s):  
Maher R. Khdour ◽  
Heba B. Awadallah ◽  
Dua’a H. Al-Hamed
Keyword(s):  
Quality Of Life ◽  
Medication Adherence ◽  
Treatment Satisfaction ◽  
Diabetic Patients ◽  
Health Related Quality ◽  
Cross Sectional ◽  
Quality Of Life Scale ◽  
Related Quality ◽  
Health Related

Objectives. This study had the goal of evaluating the role of treatment satisfaction among diabetic patients in the context of health-related quality of life (QoL) and medication adherence. Methods. This study, which utilized a cross-sectional design, was conducted at the Primary Healthcare Unit in the Ministry of Health in Ramallah between Feb. and May 2019. Medication adherence was evaluated with the 4-item Morisky Green-Levine (MGL) questionnaire, treatment satisfaction using the Treatment Satisfaction Questionnaire for Medication version 1.4 (TSQM 1.4), and health-related quality of life with the European Quality of Life scale (EQ-5D-3L). Results. Study participants consisted of 380 diabetic patients, of which 220 (57.9%) had high adherence to their medications and 160 (42.1%) had low adherence. Based on the classification of patient responses among the EQ-5D domains, pain/discomfort was the most influenced dimension, with 173 patients (36.1%) reporting problems, (36.1%). Also prominent were anxiety and depression (128 patients, 33.7%) and Mobility (115 patients, 30.3%). A significant relation was observed between QoL and treatment satisfaction (73.8 vs. 69.8; P=0.016). Treatment satisfaction also had a significant association with the anxiety domain (39.4 vs. 28.7; P=0.031). Conclusion. Participants expressed moderate satisfaction with their treatments; more satisfied patients showed greater medication adherence and had better QoL. Anxiety has been shown to be associated with reduced medication adherence and lower QoL.

scholarly journals Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence inβ-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial

Anemia ◽  
2012 ◽  
Vol 2012 ◽  
pp. 1-10 ◽  
Author(s):  
John Porter ◽  
Donald K. Bowden ◽  
Marina Economou ◽  
Jacques Troncy ◽  
Arnold Ganser ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Myelodysplastic Syndrome ◽  
Iron Overload ◽  
Treatment Satisfaction ◽  
Iron Chelation ◽  
Health Related Quality ◽  
Patient Reported ◽  
Related Quality ◽  
Health Related

Treatment of iron overload using deferoxamine (DFO) is associated with significant deficits in patients' health-related quality of life (HRQOL) and low treatment satisfaction. The current article presents patient-reported HRQOL, satisfaction, adherence, and persistence data fromβ-thalassemia (n=274) and myelodysplastic syndrome (MDS) patients (n=168) patients participating in the Evaluation of Patients' Iron Chelation with Exjade (EPIC) study (NCT00171821); a large-scale 1-year, phase IIIb study investigating the efficacy and safety of the once-daily oral iron chelator, deferasirox. HRQOL and satisfaction, adherence, and persistence to iron chelation therapy (ICT) data were collected at baseline and end of study using the Medical Outcomes Short-Form 36-item Health Survey (SF-36v2) and the Satisfaction with ICT Questionnaire (SICT). Compared to age-matched norms,β-thalassemia and MDS patients reported lower SF-36 domain scores at baseline. Low levels of treatment satisfaction, adherence, and persistence were also observed. HRQOL improved following treatment with deferasirox, particularly amongβ-thalassemia patients. Furthermore, patients reported high levels of satisfaction with deferasirox at end of study and greater ICT adherence, and persistence. Findings suggest deferasirox improves HRQOL, treatment satisfaction, adherence, and persistence with ICT inβ-thalassemia and MDS patients. Improving such outcomes is an important long-term goal for patients with iron overload.

scholarly journals Quality of life and treatment satisfaction with pharmacological interventions in Chinese adults with chronic pain due to osteoarthritis

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Qingyun Xue ◽  
Huibin Long ◽  
Jianhao Lin ◽  
Dongping Du ◽  
Jin Zhou ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Treatment Satisfaction ◽  
Brief Pain Inventory ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Knee Oa ◽  
Related Quality ◽  
Health Related ◽  
Self Assessed Health

Abstract Background Aim of this multicenter, observational, cross-sectional study was to evaluate health-related quality of life (HRQoL) and treatment satisfaction of current medications in Chinese knee OA patients. Methods Brief Pain Inventory (BPI), Treatment Satisfaction Questionnaire (TSQM-1.4), and HRQoL (EQ-5D-5L) were assessed in total of 601 OA of knee patients. Impact on QoL (EQ-5D-5L) and treatment satisfaction (TSQM-1.4) by BPI-Severity score (< 4 and ≥ 4) were presented using mean standard deviations (SDs) and were compared using a t-test. For each of self-assessed health EQ-5D-5L and TSQM, a linear regression model was used to estimate the regression coefficient along with corresponding 95% confidence interval (CI) for BPI-Severity. Results Mean score of EQ-5D-5L of patients with BPI-Severity ≥4 was significantly lower than those with BPI-Severity < 4. All the scores of TSQM in 4 dimensions were lower in patients with BPI-Severity ≥4 than in those with BPI-Severity < 4. Both HRQoL scores and TSQM scores showed a statistically significant decreasing trend with increasing BPI-Severity pain score. Conclusion Chronic knee OA pain has a significant impact on patients’ HRQoL. More severe patients with OA were less satisfied with current treatments.

scholarly journals Quality of Life and Treatment Satisfaction with Pharmacological Interventions in Chinese Adults with Chronic Pain Due to Osteoarthritis

2020 ◽  
Author(s):  
Qingyun Xue ◽  
Huibin Long ◽  
Jianhao Lin ◽  
Dongping Du ◽  
Jin Zhou ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Treatment Satisfaction ◽  
Brief Pain Inventory ◽  
Cross Sectional Study ◽  
Pharmacological Interventions ◽  
Cross Sectional ◽  
Knee Oa ◽  
Related Quality ◽  
Health Related

Abstract Background: Aim of this multicenter, observational, cross-sectional study was to evaluate health-related quality of life (HRQoL) and treatment satisfaction of current medications in Chinese knee OA patients. Methods: Brief Pain Inventory (BPI), Treatment Satisfaction Questionnaire (TSQM-1.4), and HRQoL (EQ-5D-5L) were assessed in total of 601 OA of knee patients. Results: Mean score of EQ-5D-5L of patients with BPI-Severity ≥4 was significantly lower than those with BPI-Severity <4. All the scores of TSQM in 4 dimensions were lower in patients with BPI-Severity ≥4 than in those with BPI-Severity <4. Both HRQoL scores and TSQM scores showed a statistically significant decreasing trend with increasing BPI-Severity pain score.Conclusion: Chronic knee OA pain has a significant impact on patients’ HRQoL. More severe patients with OA were less satisfied with current treatments. Trial registration (Clinical Trials identifier): Not applicable

Sign in / Sign up

Export Citation Format

Share Document